Data presented here obtained both in vitro and in vivo suggest that Beclin‐1 has a new function to maintain proper MAMs in the heart, and a specific activation of Beclin‐1 signaling can attenuate an LPS‐induced decline in MAM quality and quantity during endotoxemia. This evidence concerns the gene BECN1 and serum lipopolysaccharide activity.